Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term double-blind extension study of ritlecitinib in children and adolescents with severe alopecia areata after prior Pfizer studies
CTR20260685Phase 3Active
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Started Apr 2026; status: active.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20260685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260685.